Form 4: Teva Pharmaceutical Industries Director Janet S. Vergis Reports Acquisition of Restricted Share Units

Director Janet S. Vergis reports acquisition of 9,632 restricted share units in Teva Pharmaceutical Industries, vesting on June 6, 2025.

Summary

• Janet S. Vergis, a director of Teva Pharmaceutical Industries Ltd., filed a Form 4 on June 10, 2024, reporting a transaction.
• On June 6, 2024, Vergis acquired 9,632 restricted share units (RSUs).
• These RSUs represent a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement, as determined by the Human Resources and Compensation Committee.
• The RSUs vest on June 6, 2025.
• Following the reported transaction, Vergis directly owns 9,632 ordinary shares represented by American Depositary Shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to director compensation. The acquisition of shares can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of restricted share units by a director signals confidence in the company's future performance.

Future Outlook

The vesting of restricted share units in June 2025 could potentially increase the number of ordinary shares outstanding.

Industry Context

Director share ownership is a common practice in publicly traded companies to align management's interests with those of shareholders. This filing reflects standard reporting requirements for such transactions.

Stakeholder Impact

• The acquisition of restricted share units by a director can positively influence shareholder confidence.

Key Dates